Pacer Advisors Inc. Has $4.35 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Pacer Advisors Inc. lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 10.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,837 shares of the company's stock after acquiring an additional 3,044 shares during the quarter. Pacer Advisors Inc.'s holdings in Neurocrine Biosciences were worth $4,346,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Blue Trust Inc. increased its holdings in Neurocrine Biosciences by 75.0% during the 4th quarter. Blue Trust Inc. now owns 609 shares of the company's stock worth $83,000 after purchasing an additional 261 shares during the last quarter. Linden Thomas Advisory Services LLC grew its position in shares of Neurocrine Biosciences by 4.8% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 6,350 shares of the company's stock worth $867,000 after buying an additional 289 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Neurocrine Biosciences by 52.8% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 54,425 shares of the company's stock worth $7,429,000 after buying an additional 18,797 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in Neurocrine Biosciences by 2.1% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,133 shares of the company's stock valued at $1,110,000 after acquiring an additional 169 shares in the last quarter. Finally, Whalen Wealth Management Inc. bought a new position in Neurocrine Biosciences during the 4th quarter valued at $264,000. Institutional investors and hedge funds own 92.59% of the company's stock.

Insider Activity

In related news, insider Jude Onyia sold 2,331 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the firm's stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the sale, the insider now owns 2,507 shares of the company's stock, valued at $338,445. The trade was a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 214,799 shares of company stock worth $31,513,583 over the last three months. Corporate insiders own 4.30% of the company's stock.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX traded down $0.38 during trading hours on Friday, hitting $152.91. The stock had a trading volume of 256,569 shares, compared to its average volume of 933,406. The stock's fifty day simple moving average is $135.88 and its 200 day simple moving average is $131.44. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The firm has a market capitalization of $15.48 billion, a price-to-earnings ratio of 41.10 and a beta of 0.33.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Piper Sandler reissued an "overweight" rating and issued a $160.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. UBS Group upped their price objective on Neurocrine Biosciences from $162.00 to $176.00 and gave the company a "buy" rating in a research note on Thursday. Needham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Royal Bank of Canada dropped their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a research report on Friday, October 4th. Finally, StockNews.com downgraded shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Friday, November 1st. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Neurocrine Biosciences has a consensus rating of "Moderate Buy" and a consensus target price of $166.10.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.